Despite considerable advancement in the field of cancer therapy, cancer remains the leading cause of death worldwide. The risk of being diagnosed with cancer generally increases with age, and over this period the global population has grown, particularly in the older age groups. Further, several other lifestyle factors including tobacco use, physical inactivity, excess boy weight, and reproductive patterns also increase the risk of developing the disease. In 2021, there were more than 15 Million cancer cases with around 10 Million deaths globally. The numbers are expected to increase in coming years, which will further increase the demand of novel cancer drugs in the market.
The global top selling cancer drug market growth is driven by rise in the incidence of cancer, growing healthcare expenditure, and improved infrastructure for drug development. The increasing risk factors such as exposure to carcinogens, tobacco and alcohol use, sedentary lifestyles and infections are driving a large cancer burden. Additionally, growing awareness regarding early diagnosis and treatment has directed the anticancer drugs market to grow at significant rate.
| Drug | Company | FDA Approval | Indication | 2021 Sales | |||
| Keytruda | Merck | 2014 | melanoma, NSCLC, HNSCC, classical HL, primary mediastinal large B-cell lymphoma, urothelial carcinoma, CRC, gastric cancer, esophageal cancer, cervical cancer, hepatocellular carcinoma, Merkel cell carcinoma, renal cell carcinoma, endometrial carcinoma, tumor mutational burden-high (TMB-H) cancer, cutaneous squamous cell carcinoma, and TNBC. | US$ 17.18 Billion | |||
| Revlimid | Bristo Myers Squibb | 2005 | Multiple myeloma, Follicular Lymphoma, myelodysplastic syndromes, mantle cell lymphoma, marginal zonal lymphoma | US$ 12.8 Billion | |||
| Opdivo | Bristo Myers Squibb | 2014 | NSCLC, malignant pleural mesothelioma, renal cell carcinoma, classical Hodgkin lymphoma, HNSCC, urothelial carcinoma, CRC, hepatocellular carcinoma, esophageal cancer, gastric cancer, and gastroesophageal junction cancer. | US$ 7.52 Billion | |||
| Imbruvica | AbbVie | 2015 | Mantle Cell Lymphoma; Chronic Lymphocytic Leukemia; Waldenström’s Macroglobulinemia; Small Lymphocytic Lymphoma; Marginal Zone Lymphoma | US$ 5.4 Billion | |||
| Ibrance | Pfizer | 2015 | Breast Cancer | US% 5.43 Billion | |||
| Perjeta | Genentech | 2012 | Breast Cancer | US$ 4.28 Billion | |||
| Tecentriq | Genentech | 2016 | Bladder Cancer, NSCLC, Breast Cancer, Small Cell Lung Cancer, Hepatocellular Carcinoma, Melanoma | US$ 3.58 Billion | |||
| Avastin | Genentech | 2004 | Colorectal Cancer, Non-Small Cell Lung Cancer, Glioblastoma Multiforme, Renal Cell Carcinoma, Cervical Cancer, Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Hepatocellular Carcinoma | US$ 3.3 Billion | |||
| Herceptin | Genentech | 1998 | Breast Cancer, Gastric Cancer | US$ 2.91 Billion | |||
| Rituximab | Genentech | 1997 | Chronic Lymphocytic Leukemia, Rheumatoid Arthritis, Non-Hodgkin’s Lymphoma, Granulomatosis with Polyangiitis, Microscopic Polyangiitis, Pemphigus | US$ 2.77 Billion | |||
| Darzalex | Janssen Biotech | 2015 | Multiple Myeloma | US$ 1.64 Billion | |||
| Xtandi | Astellas Pharma | 2012 | Prostate Cancer | US$ 1.18 Billion | |||
| Venclexta | Abbvie | 2016 | Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia | US$ 934 Million | |||
| Gazvya | Genentech | 2013 | Chronic Lymphocytic Leukemia, Follicular Lymphoma | US$ 733 Million | |||
| Jakafi | Incyte Corporation | 2011 | Myelofibrosis | US$ 592 Million | |||
Recent Research Publications By Kuick Research:
- Global LAG 3 Inhibitor Clinical Trials & Market Opportunity Insight 2028
- Global TIGIT Inhibitor Drug Opportunity & Clinical Research Insight 2022
- Global Trispecific Antibody Market Opportunity & Clinical Trials Insight 2028
- Global TROP2 Antibody Market & Clinical Trials Insight 2026
- Global B Cell Maturation Antigen (BCMA) Targeted Therapy Market & Clinical Trials Insight 2026
- Global TRK Inhibitors Market, Drug Sales & Clinical Trials insight 2026
- Trodelvy Patent, Sales & Clinical Trials Insight 2028
- Unituxin Patent, Sales & Clinical Trials Outlook 2028
- Trikafta Patent, Sales & Clinical Trials Insight 2028
- Rybrevant Bispecific Antibody Patent, Sales & Clinical Trials Outlook 2028
- Danyelza Patent, Sales & Clinical Trials Outlook 2028
- Ayvakit Patent, Sales & Clinical Trials Insight 2028
- Global MEK Inhibitors Market, Drug Sales & Clinical Trials insight 2026
- Global Cell Therapy Market Outlook, Patent & Clinical Trials Insight 2028
- US Biosimilar Insulin Market Opportunity & Clinical Trials Insight 2026
- Europe Biosimilars Market, Dosage, Price, Sales & Clinical Trials Insight 2026
- Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity & Clinical Trials Insight 2026
- Global Bispecific Antibody Market Opportunity, Drug Sales, Price & Clinical Trials Insight 2028
- Global EZH2 Inhibitor Market Opportunity, Sales & Clinical Trials Insight 2026
- Lumakras Drug Clinical Insight & Sales Forecast 2026
- Gamma Delta T Cell Cancer Therapy Opportunity & Clinical Trials Insight 2026
- Global CFTR Modulators Market Opportunity, Dosage, Price & Clinical Trials Insight 2026
- Global Peptide Cancer Vaccine Market & Clinical Trials Insight 2026
- Global Peptide Drug Conjugate Market & Clinical Trials Insight 2026
- Global C5 Complement Inhibitors Drug Market Opportunity, Drug Price, Sales & Clinical Trials Insight 2026
- Global Anaplastic Lymphoma Kinase ALK Inhibitors Market & Clinical Trials Insight 2026
For Report Sample Contact:
Neeraj Chawla
Research Head
Kuick Research
+91-9810410366